The findings in the experimental use of a new retrosteroide (1-Dihydro-6-Chlor-retroprogesterona) for the treatment of menstrual disorders, constant anovulation or luteal insufficiency in 97 patients were analyzed and compared to observations in 9 patients who received only placebo . This allows us to hold the following suggestions regarding the therapeutic value: 1.-When the endogenous estrogen secretion is adequate and there is no organic lesion disorders are corrected in most patients; 2. is a weak inducer of ovulation. Clomiphene citrate was effective in some patients who premedication with compound retrosteroide had failed; 3. The therapeutic effectiveness in luteal insufficiency is higher, however, a patient in the control group corrected his condition while receiving placebo; 4. The proposed dose not inhibit ovarian function while acting as a progestational agent. It therefore see...

A comparative clinical evaluation of a comprehensive contraceptive program that began in 1964 in the areas of Health North and West of Santiago, was made using theoretical methods of life up to 36 months of use. Lippes Loop-D were inserted intermenstrually to 14,579 women; TCu-200 (only 12 months of use) to 350 women; Medroxyprogesterone Acetate was administered intramuscularly in dose of 150 mg. every 3 months 561 women and 300 mg. every six months to 588. The percentage of patients who discontinued treatment were influenced mainly by age, similarity and the desire for future pregnancies.